Tag: Immunotherapy

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy

September 19, 2024

“We explore how integrating these technologies could revolutionize personalized oncology.” BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled,… read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

“[...] there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.” BUFFALO, NY- August 21,… read more

Oncotarget

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

June 26, 2024

“Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.” BUFFALO, NY- June 26, 2024 – A new research perspective was… read more

Oncotarget

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

June 21, 2023

“[...] the experience with GITR targeting in patients may inform the development of either novel or next-generation immunotherapy approaches.” BUFFALO, NY- June 21, 2023 – A new research perspective was… read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

“[...] large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.” Listen to an audio… read more

Figure 1: Demographic factors, comorbidities and therapy regime of the melanoma patients in percentage, age in years.

Oncotarget

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma

January 11, 2023

“In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” BUFFALO, NY- January 11, 2023 – A new research… read more

Figure 4: Wnt pathway expression in tumors from NeuT/ATTAC mice.

Oncotarget

Oncotarget | Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy is Associated With Macrophage Infiltration and Wnt Pathway Expression

January 5, 2023

“One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” Listen to an audio version of this press release… read more

Oncotarget

Oncotarget | Combined Epigenetic and Immunotherapy for Blastic and Classical Mantle Cell Lymphoma

December 13, 2022

“Here, we describe results using cladribine based combination epigenetic and immunotherapy in MCL [mantle cell lymphoma].” BUFFALO, NY- December 13, 2022 – A new research paper was published in Oncotarget's… read more

Oncotarget

Oncotarget | Site of Analysis Matters – Ongoing Complete Response to Nivolumab in Patient With HIV/HPV Related Metastatic Anal Cancer and MLH1 Mutation

September 29, 2022

“This case report represents an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB), and an ongoing response to Nivolumab.” Listen… read more

Oncotarget

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

July 19, 2022

“Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.” Listen to an audio version of this press release BUFFALO, NY- July 19,… read more